{"brief_title": "Initial Phase II Efficacy and Safety Study of SC-48334 Administered in Combination With Low-Dose Zidovudine (AZT) to Symptomatic HIV-1 Infected Patients With = or > 200 to = or < 500 CD4+ Cells/mm3", "brief_summary": "The primary objective of this study is to determine the preliminary efficacy and tolerability of combining a selected dose of SC-48334 with low-dose AZT in the treatment of symptomatic HIV+ patients with 200 to 500 CD4+ cells/mm3. The secondary objective is to determine the pharmacokinetics and bioavailability of both SC-48334 and AZT, when administered together, in symptomatic HIV+ patients with 200 - 500 CD4+ cells/mm3.", "condition": ["HIV Infections"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["Butyldeoxynojirimycin", "Zidovudine"], "criteria": "Inclusion Criteria Concurrent Medication: Allowed: - Medications for the prophylaxis of opportunistic infections, such as: - Aerosolized pentamidine. - Trimethoprim/sulfamethoxazole. - Nystatin. - Clotrimazole. - Anti-mycobacterial agents. - Ganciclovir. - Topical acyclovir. Patients must have the following: - CD4+ cells counts = or > 200 < 500 /cell mm3. - For purposes of inclusion the absolute CD4+ cell count must be = or > 200 < 500 cells/mm3 on the first sample and = or > 190 < 510 cells/mm3 on the second sample. - Have at least one of the following: - Oral candidiasis. - Herpes zoster during the last 3 years. - Oral hairy leukoplakia during the past three years. - Chronic ( > 30 day period), recurrent seborrheic dermatitis, or topical, pruritic folliculitis (itchy bumps). - Unintentional weight loss in excess of 10 pounds or 10 percent of usual body weight. - Chronic fatigue present for the past 6 months, which has interfered with normal activity at least 1 to 2 times per week. - HIV antibody positive as determined by federally licensed Enzyme-linked Immunosorbent Assay (ELISA). - Documented, written informed consent must be obtained prior to admission to the study. Prior Medication: Allowed for no more than 12 weeks prior to study entry: - Zidovudine (AZT). Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: - Malignancies, with the exception of basal cell carcinoma. - Significant organ dysfunction. Concurrent Medication: Excluded: - All anti-retroviral drugs with the exception of Zidovudine. Cancer chemotherapeutic agents. - Anti-metabolites and alkylating agents. - All investigational non-FDA approved drugs. Patients with the following are excluded: - Clinically significant diarrhea (> 3 liquid stools per day for > 7 days) without definable cause, within 6 months prior to enrollment). - Diarrhea, as above, with known, non-HIV related cause occurring within one month prior to enrollment. - Meets CDC criteria for AIDS classification. - Chronic fever (> 38.5 C persisting for more than 14 consecutive days, or for more than 15 days in any 30-day interval prior to study entry). - Malignancies, with the exception of basal cell carcinoma. - Significant organ dysfunction. - Known hypersensitivity to SC-48334 or related compounds. - History of lactose intolerance. Prior Medication: Excluded within 30 days of study entry: - Any investigational medication. - Treatment with a drug (other than Zidovudine) with anti-HIV activity. - Excluded for > 12 weeks prior to study entry: - Zidovudine (AZT). - Excluded within 90 days of study entry: - Ribavirin. - Excluded within 6 months of study entry: - Cancer chemotherapy. - Excluded: - Treatment with SC-48334. Prior Treatment: Excluded within 30 days of study entry: - Electron beam radiation. - Excluded within 6 months prior to study entry: - Required HIV-related blood transfusions. - Whole body radiation. Current use of illicit substances; or current abuse of alcohol, the use of which would limit compliance with the protocol.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Zidovudine", "mesh_term": ["HIV Infections", "Zidovudine", "Miglustat"], "id": "NCT00001993"}